This BBC podcast is supported by ads outside the uk Available now on the documentary from the BBC World Service.
Canada is a nation built through generations of newcomers.
But now an asylum backlog coupled with a housing shortage means most Canadians are now questioning immigration levels.
Some are calling for a moratorium on immigration, though others say it's needed to ensure Canada's long term survival.
Listen now by searching for the documentary wherever you get your BBC podcasts.
Welcome to the Inquiry with me, Tania Beckett from the BBC World Service.
One question for expert witnesses and an answer.
It's a disease that will affect one in five people in our lifetime and the number is growing.
In fact, there are estimates that in 2025, around 20 million people worldwide will be DIA with some form of cancer.
But just as the world of medicine has tackled many other diseases with the use of vaccines, it's becoming increasingly hopeful that they could also become a means to treat cancer.
And moves are already afoot.
We'll return to our main story, which is about a groundbreaking new vaccine for melanoma skin cancer, which is being trialled in the UK.
In April 2024, a melanoma jab was trialled on patients in the UK.
A lung cancer vaccine is being trialled across seven countries.
And the University of Florida has developed a cancer vaccine that reprograms the immune system to attack the most common type of brain cancer.
This sudden rush of new treatments can be traced back to a new technology rolled out during the pandemic, namely a groundbreaking type of vaccine which is much more agile than traditional vaccine technology and is called mRNA.
So with all the promise that these new cancer vaccine trials bring for cancer patients, this week on the inquiry we're asking, are we close to a cancer vaccine?
Part 1 Understanding cancer.
If we are to understand why cancer could in the future be treated with a vaccine, we first need to examine what the disease is and, and how it affects the body.
Our first expert witness is Meredith McCain, Director of Melanoma and skin cancer research at Sarah Cannon Research Institute in the usa.